The Latest Breaking News from Novo Nordisk

Trump’s tariffs on EU goods could slash exports by at least €85 billion, hitting autos and pharmaceuticals hardest. Germany, Denmark and Central Europe face sharp fallout, raising recession risks and forcing the ECB to consider rate cuts.

The market appears to be underestimating just how much these two companies can grow.

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several disappointing trial results. However, analysts remain optimistic about the shares, forecasting a potential price upside of up to 60% over the next 12 months.

Potential US tariffs on pharmaceuticals could set off a ripple effect that extends far beyond the immediate price hikes, as both the US and Europe heavily rely on each other.

The World Health Organization states that there were around 830 million people living with diabetes in 2022. More than half of them weren't taking diabetes medications, including insulin, likely due to access and cost issues.

The German software company's share price gained 40% in the past year, while Danish drugmaker Novo Nordisk has gradually lost almost half of its own since last summer.

The Slovakian rider outsprints Benjamin Thomas and Niklas Larsen for the victory in Cholet

Russia has a new business elite and radically altered marketplace—and it’s done away with key legal protections.

"The Ozempic face is crazy and her fillers are terrible" The post Katy Perry Flaunts Her Weight Loss After Addressing Ozempic Rumors: “She Looks Worse” first appeared on Bored Panda.

Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.

Research shows weight loss-inducing semaglutide medicines can help lower the risk of cardiovascular conditions and sleep apnea